Autolus Therapeutics Unlocks Long-Term Remission Potential with Obe-Cel

Autolus Therapeutics shares are trading higher after presenting positive long-term follow-up data from the FELIX study, highlighting Obe-Cel's potential for long-term remission in relapsed/refractory B-cell acute lymphoblastic leukemia patients.